Interaction Checker

Bendamustin etkileşimleri

Bendamustin (Treanda, Bendeka, Belrapzo) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 91 belgelenmiş etkileşim var: 2 majör, 89 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (2)

  • Allopurinolksantin oksidaz inhibitörüMajör

    However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly. [see Warnings and Precautions (5.6) ] 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride injection treatment in clinical trials and postmarketing safety reports, including… (Bendamustin etiketi, Uyarılar ve önlemler)

  • RituksimabimmünosüpresanMajör

    Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (Bendamustin etiketi, Uyarılar ve önlemler)

Orta düzey etkileşimler (89)

  • AbataseptimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • AbrositinibJAK inhibitörüOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • AdalimumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • AlemtuzumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • AzatioprinimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • AzelastinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Azelastin ve flutikazonantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • BarisitinibJAK inhibitörüOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • BeklometazonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • BetametazonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Bromfeniramin, psödoefedrin ve dekstrometorfanantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • BudesonidkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Deferasiroksdemir takviyesiOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • DeflazakortkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DeksametazonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DeksklorfeniraminantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DesloratadinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DesonidkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DifenhidraminantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DimenhidrinatantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Dimetil fumaratimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • DoksilaminantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Doksilamin ve piridoksinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • EtanerseptimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • EverolimusimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FeksofenadinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FingolimodimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FludrokortizonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FlunisolidkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FluosinonidkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FlutikazonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • FluvoksaminSSRIOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • GuselkumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • HalobetazolkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Hidrokodon ve klorfeniraminopioidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • HidrokortizonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • HidroksizinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • İnfliksimabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Kannabidiol (reçeteli)antikonvülsanOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanOrta

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Bendamustin etiketi, İlaç etkileşimleri)

  • KarbinoksaminantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • KladribinantimetabolitOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • KlemastinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • KlobetazolkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • KlorfeniraminantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • LeflunomidimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • LevosetirizinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Lopinavir ve ritonavirantiretroviralOrta

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Bendamustin etiketi, İlaç etkileşimleri)

  • LoratadinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MeklizinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MeksiletinantiaritmikOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • MerkaptopürinantimetabolitOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MetilprednizolonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MetotreksatimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MikofenolatimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • MometazonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • NatalizumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • OkrelizumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • OlopatadinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Olopatadin ve mometazonantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Pimekrolimuskalsinörin inhibitörüOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • PonesimodimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • PrednizolonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • PrednizonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • PrometazinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Prometazin ve dekstrometorfanantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Prometazin ve kodeinopioidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • RitlesitinibJAK inhibitörüOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • RitonavirantiretroviralOrta

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Bendamustin etiketi, İlaç etkileşimleri)

  • SekukinumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SetirizinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SiklesonidkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SiklofosfamidimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SiklosporinimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SimetidinH2 blokeriOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • SiprofloksasinflorokinolonOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • SiproheptadinantihistaminikOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • SirolimusimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • TeriflunomidimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • TofasitinibimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • TosilizumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • TriamsinolonkortikosteroidOrta

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Bendamustin etiketi, Uyarılar ve önlemler)

  • UpadasitinibimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • UstekinumabimmünosüpresanOrta

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

  • Viloksazinnoradrenalin geri alım inhibitörüOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

  • ZileutonCYP1A2 inhibitörüOrta

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Bendamustin etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Bendamustin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.